Prevention of perinatal transmission of human immunodeficiency virus: A progress report 2 years after completion of AIDS Clinical Trials Group trial 076

Clinical Infectious Diseases

Volumn 23, Issue 3, 1996, Pages 438-441

  Wilfert, Catherine M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; NOTE; PATIENT COUNSELING; PERINATAL PERIOD; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0029787472     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.3.438     Document Type: Note

References (19)

1. Centers for Disease Control and Prevention. Zidovudine for the prevention of HIV transmission from mother to infant. MMWR Morb Mortal Wkly Rep 1994;43:285-7.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
3. Connor E, Sperling R, Shapiro D, Oleske J, Fowler NG, Protocol 076 and 219 Study Groups. Long-term effect of zidovudine (ZDV) exposure among uninfected infants born to HIV infected mothers in Pediatric AIDS Clinical Trials Group (ACTG) Protocol 076 [abstract no 11]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:205.
4. Centers for Disease Control and Prevention. Recommendations for the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43 (no RR-11): 1-20.
5. Provisional Committee on Pediatric AIDS. Perinatal human immunodeficiency virus testing. Pediatrics 1995;95:303-7.
6. Centers for Disease Control and Prevention. U.S. Public Health Service recommendations for HIV counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep 1995;44 (no RR-7):1-15.
7. Matheson PB, Abrams EJ, Thomas PA, et al. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 1995;172:353-8.
8. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA 1994;271:1925-30.
9. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of ZDV therapy on transmission in rural and urban counties. JAMA 1996;275:1483-8.
10. Cooper E, Diaz C, Pitt J, et al. Impact of ACTG 076: use of zidovudine during pregnancy and changes in the rate of HIV vertical transmission [abstract no 26]. In: Program and abstracts of the 3rd Conference on Retrovirus and Opportunistic Infections (Washington, DC). Alexandria, VA: American Society for Microbiology, 1996.
11. Oliveira RH, Mitchell C, Gomez-Marin O, et al. Maternal zidovudine (ZDV) use and the vertical transmission of HIV-1 (VT) [abstract no 129]. In: Program and abstracts of the 3rd Conference on Retrovirus and Opportunistic Infections (Washington, DC). Alexandria, VA: American Society for Microbiology, 1996.
12. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1996; 275:599-605.
13. Weiser B, Nachman J, Tropper P, et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. Proc Natl Acad Sci USA 1994;91:8037-41.
14. Shaffer N, Chotpitayasunondh T, Roongpisuthipong A, et al. High maternal viral load predicts perinatal HIV-1 transmission and early infant progression [abstract no 30]. In: Program and abstracts of the 3rd Conference on Retrovirus and Opportunistic Infections (Washington, DC). Alexandria, VA: American Society for Microbiology, 1996.
15. Sperling RS, Shapiro DE, Coombs R, et al. Maternal plasma HIV-1 RNA and the success of zidovudine in the prevention of mother-child transmission [abstract no LB1]. In: Program and abstracts of the 3rd Conference on Retrovirus and Opportunistic Infections (Washington, DC). Alexandria, VA: American Society for Microbiology, 1996.
16. Koup RA, Cao Y, Ho DD, et al. Lack of maternal viral threshold for vertical transmission of HIV-1 [abstract LB-2]. In: Program and abstracts of the 3rd Conference on Retrovirus and Opportunistic Infections (Washington, DC). Alexandria, VA: American Society for Microbiology, 1996.
17. Burchette SK, Kornegay J, Pitt J, et al. Assessment of maternal plasma HIV viral load as a correlate of vertical transmission [abstract no LB-3]. In: Program and abstracts of the 3rd Conference on Retrovirus and Opportunistic Infections (Washington, DC). Alexandria, VA: American Society for Microbiology, 1996.
18. Wilfert CM. Mandatory screening of pregnant women for the human immunodeficiency virus. Clin Infect Dis 1994;19:664-6.
19. Davis SF, Byers RH Jr, Lindegren MC, et al. Prevalence and incidence of vertically acquired HIV infection in the U.S. JAMA 1995;247:952-5.